lfs epoxiconazol-pyraclostrobin suspoemulsion
lfs kemi - epoxiconazol, pyraclostrobin - suspoemulsion - 50 g/l epoxiconazol ; 133 g/l pyraclostrobin
lfs epoxiconazol-boscalid suspensionskoncentrat
lfs kemi - epoxiconazol, boscalid - suspensionskoncentrat - 67 g/l epoxiconazol ; 233 g/l boscalid
to epoxiconazol suspensionskoncentrat
agros - epoxiconazol - suspensionskoncentrat - 125 g/l epoxiconazol
lfs epoxiconazol+pyraclostrobin+boscalid od-formulering
lfs kemi - epoxiconazol, pyraclostrobin, boscalid - od-formulering - 50 g/l epoxiconazol ; 60 g/l pyraclostrobin ; 140 g/l boscalid
lfs epoxiconazol suspensionskoncentrat
lfs kemi - epoxiconazol - suspensionskoncentrat - 125 g/l epoxiconazol
zeposia
bristol-myers squibb pharma eeig - ozanimod hydrochlorid - multiple sclerosis, relapsing-remitting; colitis, ulcerative - immunosuppressiva - multiple sclerosiszeposia is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (rrms) with active disease as defined by clinical or imaging features. ulcerative colitiszeposia is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.
maredo 125 sc suspensionskoncentrat
adama northern europe b.v. - epoxiconazol - suspensionskoncentrat - 125 g/l epoxiconazol
bell suspensionskoncentrat
basf a/s - epoxiconazol, boscalid - suspensionskoncentrat - 67 g/l epoxiconazol ; 233 g/l boscalid
ceando suspensionskoncentrat
basf a/s - epoxiconazol, metrafenon - suspensionskoncentrat - 83 g/l epoxiconazol ; 100 g/l metrafenon
opera suspensionskoncentrat
basf a/s - epoxiconazol, pyraclostrobin - suspensionskoncentrat - 50 g/l epoxiconazol ; 133 g/l pyraclostrobin